ArticleJournal of biological engineering2025
Development of predictable and high-yield CHO cell line by site-specific integration.
Article in Journal of biological engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Plant-based production and characterization of monoclonal antibodies targeting extracellular enveloped proteins of the Mpox Virus.Biotechnology reports (Amsterdam, Netherlands) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chinese hamster ovary (CHO) cell is a widely used cell line for the production of therapeutic proteins. Customarily, CHO host cell line is established through random integration, which requires multiple rounds of screening to identify the optimal producer. In contrast, site-specific integration (SSI) technology can boost cell line development efficiency by directing gene of interest (GOI) to certain genomic loci that supports sustained and stable expression. In this study, by utilizing AI algorithms and robotic systems, we have identified several CHO host cell lines carrying marker gene by Bxb1-mediated SSI technology. After the substitution of marker gene with different types of GOI at specific sites, some of cases delivered a titer exceeding 15 g/L. Thanks to the uniformity of SSI cell lines, protein titer and quality of monoclonal cells can be predicted based on the performance of corresponding minipools. Different monoclonal cells originated from the same minipool also showed consistent protein quality. Furthermore, it was observed that the monoclonal cells obtained by SSI demonstrated consistency in protein titer, quality and genetic stability after 26 consecutive passages (approximately 90 days). In summary, we have successfully developed an effective platform for the construction of SSI cell lines, which allows the rapid and efficient expression of various proteins while maintaining consistency in stability and product quality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.